Company profile
UK company SC362461, incorporated on 10 July 2009.
Ubiquigent - Driving DUB drug discovery and development
Ubiquigent has an unrivalled track record and unique range of specialist services focused on the exploitation of the DUB enzymes and ubiquitin-proteasome system
Company number SC362461
Updated 07 Jul 2026 09:49
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Company registered at Companies House
The company has been set up to market reagents, assays, services and technologies developed by the Protein Ubiquitylation Unit of the Scottish Institute for Cell Signaling which was set up as a result of my research into the role of ubiquitylation in studying the innate immune system.; http://www.ubiquigent.com
MRC Technology holds 10% of the equity in Ubiquigent Limited.
1 Jan 2018 to 31 Dec 2018
With a growing and ageing population, the burden of chronic diseases is the UK’s greatest societal challenge. Thus there is an urgent need for new medicines to address the increasing impact on the population of chronic neurodegenerative diseases, including Parkinson’s, Alzheimer’s, Huntington’s and Amyotrophic Lateral Sclerosis that lead to dementia, move...
1 Jan 2017 to 31 Dec 2017
Despite advancements in the pharmaceutical industry there remains a significant need for new therapies to address unmet clinical needs. The ubiquitin system defines a cascade of proteins that control regulated protein turnover amongst other functions. Its key role in the regulation of probably the majority if not all cellular proteins and processes means ...
